Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
206
Active:7
Completed:13
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:27
Phase 2:100
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (175 trials with phase data)• Click on a phase to view related trials
Phase 2
100 (57.1%)Not Applicable
34 (19.4%)Phase 1
27 (15.4%)Phase 3
8 (4.6%)Phase 4
4 (2.3%)Early Phase 1
2 (1.1%)Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Not Applicable
Recruiting
- Conditions
- Primary/Secondary PreventionHigh Risk for Febrile Neutropenia of Chemotherapy RegimensIntermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
- Interventions
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 1076
- Registration Number
- NCT07187908
- Locations
- 🇨🇳
The Henan cancer hospital, Zhengzhou, Henan, China
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
Not Applicable
Not yet recruiting
- Conditions
- Breast CancerHER2 + Breast Cancer
- Interventions
- Drug: Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT07136974
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT07125950
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
Not Applicable
Not yet recruiting
- Conditions
- Resectable Stage II-IIIB NSCLC
- Interventions
- Drug: Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT07108816
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
Not Applicable
Recruiting
- Conditions
- HER2-positive Advanced Breast CancerBrain MetastasesRadiotherapy
- Interventions
- Radiation: FSRT or WBRT
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 224
- Registration Number
- NCT07100600
- Locations
- 🇨🇳
Professor, Zhengzhou, Henan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 41
- Next
News
Immunotherapy-Enhanced Total Neoadjuvant Therapy Shows Promise for Locally Advanced Rectal Cancer
Two multi-institutional studies demonstrate that combining immune checkpoint inhibitors with total neoadjuvant therapy (TNT) achieves superior pathological complete response rates compared to standard chemoradiotherapy in microsatellite stable locally advanced rectal cancer patients.